Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Per Norlén"'
Autor:
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in
Externí odkaz:
https://doaj.org/article/ac146a36143540ed83d59ae4ac9773f4
Publikováno v:
Therapeutic Advances in Vaccines and Immunotherapy, Vol 6 (2018)
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and s
Externí odkaz:
https://doaj.org/article/80d2d51011424c3d8e93c13cc809d9a2
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Purpose: Local administration of immune-activating antibodies may increase the efficacy and reduce the immune-related adverse events associated with systemic immunotherapy of cancer. Here, we report the development and affinity maturation of a fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd6e11c37ca63c54a2a274a63887800
https://doi.org/10.1158/1078-0432.c.6524333.v1
https://doi.org/10.1158/1078-0432.c.6524333.v1
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Figure 3. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor inoculation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3452b53c78c750759d06b3ae34d25e1
https://doi.org/10.1158/1078-0432.22459901
https://doi.org/10.1158/1078-0432.22459901
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Figure 2. Microphotographs from cryo sections showing representative images of A) Spleen, B) Liver and C) Brain (one slide representing data from one female and one male mice) from hCD40+ mice stained with an anti-human CD40 antibody or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542a8b1c20d7cd6b01db3b74579a38c4
https://doi.org/10.1158/1078-0432.22459904.v1
https://doi.org/10.1158/1078-0432.22459904.v1
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Figure 1. A) Annexin V positive moDC after ADC-1013 stimulation and B) the effect of cross-linking on percentage of Annexin stained cells (n=6).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ba60817ec53edde1ff897433a09d88
https://doi.org/10.1158/1078-0432.22459907
https://doi.org/10.1158/1078-0432.22459907
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Figure 6. Splenocytes from complete responders (CR) from ADC-1013 treatment of MB40 tumors were transplanted to naive mice. The receiving naïve mice were then challenged with MB49 tumors and the tumor volume followed over time until th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5660a3536345e5fd8d638b17cfbdf7ee
https://doi.org/10.1158/1078-0432.22459892
https://doi.org/10.1158/1078-0432.22459892
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Figure 5. hCD40tg mice with one tumor on each flank were treated peritumorally in the tumor on the right flank. Tumor volumes of individual untreated tumors (red) and treated tumors (black) are displayed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::224275f6f026be728757821868949d1c
https://doi.org/10.1158/1078-0432.22459895
https://doi.org/10.1158/1078-0432.22459895
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53cc12a7928da6b3f03385ba3f4e7caf
https://doi.org/10.1158/1078-0432.22459889.v1
https://doi.org/10.1158/1078-0432.22459889.v1
Autor:
Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo
Supplementary Table 1. Selection strategy Supplementary Table 2. Kinetic parameters for ADC-1013 and B44 measured by Biacore Supplementary Table 3. In vitro potency (EC50) of ADC-1013 in DC and B cell assays Supplementary table 4. Phenotypic profilin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2804768385233f8099f93098c871c58d
https://doi.org/10.1158/1078-0432.22459886.v1
https://doi.org/10.1158/1078-0432.22459886.v1